Hints and tips:
...Large pharma companies like Sanofi and GSK are hoping to shake off their image as laggards, while start-ups such as Novavax, CureVac and Valneva see opportunities to satisfy unmet needs....
...When Hopp, a co-founder of tech group SAP, first agreed to invest roughly €2m in CureVac in 2005, he wanted to “make sure that we build infrastructure and new jobs here in Germany”, von Bohlen recalled....
...When pharma companies were retrenching 10 years ago, he suspects early stage vaccine programmes were among those cut....
...Eisai alone has transferred licences for about 60 medicines to Germany — at a cost of about €7,200 each simply to change the name of the licence holder from “Eisai Europe in Hatfield” to “Eisai GmbH in Frankfurt...
...In the US, Nestlé’s Galderma unit markets a rival, known as Dysport, while Germany's Merz pharma sells a neurotoxin under the Xeomin brand....
...Botox is the leading wrinkle smoother, with a global market share of roughly 85 per cent, although dermatologists say it still faces fierce competition from drugs such as Nestlé’s Dysport and Merz Pharma...
...In December, the US Food and Drug Administration approved for sale a new drug, TriLipix, for cholesterol and triglycerides that Solvay co-markets with Abbott....
...Solvay retained a string of investment banks this year to explore options for the pharma division and attracted preliminary interest from several large pharmaceuticals companies before many dropped out....
International Edition